Scientists are increasingly investigating retatrutide, a promising medication from Eli Lilly, as a potential step in weight management. Different than many earlier approaches, retatrutide is a twin-action receptor targeting simultaneously GLP-1 and GIP, chemicals that affect appetite and blood g